CERRITOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its fourth quarter & full year 2022 financial results after the market close on Thursday, March 9, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13735751. The replay will be available until March 16, 2023.
Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.
About The Oncology Institute
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Media
The Oncology Institute
Julie Korinke
This email address is being protected from spambots. You need JavaScript enabled to view it.
(562) 735-3226 x 88806
Investors
Solebury Strategic Communications
Maria Lycouris
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.16 |
Daily Change: | 0.22 11.34 |
Daily Volume: | 932,229 |
Market Cap: | US$163.210M |
March 24, 2025 November 13, 2024 November 11, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load